"I am referring to Resverlogix news releasing on something material between Dec 10 and Jan 10 that would increase the share price and market cap."

For example, a potential top-line news release on stellar improvement in renal function by eGFR change in the CKD sub-study would be pretty sweet. Even though the full results may not be presented and/or published until March, nothing stopping a top-line news release on the CKD sub-study in my opinion.

We already know there was the incredible ~50% RRR in 3-point MACE in this CKD population. It would be a pretty big splash in my opinion if that MACE reduction in the CKD sub-study was also coupled with eGFR improvements vs. baseline and/or placebo.

BDAZ